Lung function parameters in omalizumab responder patients: An interesting tool?

• Published in: Allergy (Copenhagen) 2017-12, Vol.72 (12), p.1953-1961
• Main Authors: Paganin, F., Mangiapan, G., Proust, A., Prudhomme, A., Attia, J., Marchand‐Adam, S., Pellet, F., Milhe, F., Melloni, B., Bernady, A., Raspaud, C., Nocent, C., Berger, P., Guilleminault, L.
• Format: Article
• Language: English
• Subjects: Adult; Aged; Anti-Asthmatic Agents - therapeutic use; Asthma; Asthma - diagnosis; Asthma - drug therapy; Asthma - physiopathology; Female; FEV1; Humans; Immunoglobulin E; Immunotherapy; lung function; Lungs; Male; Middle Aged; Monoclonal antibodies; omalizumab; Omalizumab - therapeutic use; Respiratory function; Respiratory Function Tests; Retrospective Studies; Time Factors; Treatment Outcome
• ISSN: 0105-4538; 1398-9995
• DOI: 10.1111/all.13202

Background Omalizumab, an anti‐IgE antibody, is used to treat patients with severe allergic asthma. The evolution of lung function parameters over time and the difference between omalizumab responder and nonresponder patients remain inconclusive. The objective of this real‐life study was to compare the changes in forced expiratory volume in 1 second (FEV1) of omalizumab responders and nonresponders at 6 months. Methods A multicenter analysis was performed in 10 secondary and tertiary institutions. Lung function parameters (forced vital capacity (FVC), pre‐ and postbronchodilator FEV1, residual volume (RV), and total lung capacity (TLC) were determined at baseline and at 6 months. Omalizumab response was assessed at the 6‐month visit. In the omalizumab responder patients, lung function parameters were also obtained at 12, 18, and 24 months. Results Mean prebronchodilator FEV1 showed improvement in responders at 6 months, while a decrease was observed in nonresponders (+0.2±0.4 L and −0.1±0.4 L, respectively, P